DURATION OF DIABETES AND CARDIORENAL EFFICACY OF LIRAGLUTIDE AND SEMAGLUTIDE: A POST HOC ANALYSIS OF THE LEADER AND SUSTAIN-6 CLINICAL TRIALS

被引：0
|
作者：
Verma, Subodh [1 ]
Bain, Stephen C. [1 ]
Honore, Julie Broe [1 ]
Fries, Tea Monk [1 ]
Nauck, Michael A. [1 ]
Pratley, Richard E. [1 ]
Rasmussen, Soren [1 ]
Zinman, Bernard [1 ]
Buse, John [1 ]
机构：
[1] Novo Nordisk AS, Soborg, Denmark
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 09期
关键词：
D O I：
10.1016/S0735-1097(19)32310-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1024-05
引用
收藏
页码：1704 / 1704
页数：1
相关论文
共 50 条
  • [41] Semaglutide reduced cardiovascular events regardless of metformin use: a post hoc exploratory subgroup analysis of SUSTAIN 6 and PIONEER
    Husain, M.
    Consoli, A.
    De Remigis, A.
    Meyer, A. S. P.
    Rasmussen, S.
    Bain, S.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 14 - 14
  • [42] Effect of semaglutide on MACE by baseline kidney function in participants with type 2 diabetes and high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc analysis
    Rossing, P.
    Bain, S.
    Bosch-Traberg, H.
    Frenkel, O.
    Heerspink, H. L.
    Rasmussen, S.
    Mellbin, L.
    [J]. DIABETOLOGIA, 2022, 65 (SUPPL 1) : S24 - S25
  • [43] Efficacy and Safety of Semaglutide 0.5 mg vs. Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 7
    Pratley, Richard E.
    Aroda, Vanita R.
    Gondolf, Theis
    Hansen, Thomas
    Lingvay, Ildiko
    Luedemann, Joerg
    Skjoeth, Trine Vang
    Viljoen, Adie
    [J]. DIABETES, 2019, 68
  • [44] Efficacy and safety of semaglutide by background sodium-glucose cotransporter-2 inhibitor: a post hoc analysis of SUSTAIN 9
    Ludvik, B.
    Bhosekar, V.
    Busch, R. S.
    Holst, I.
    Philis-Tsimikas, A.
    Thrasher, J.
    Woo, V. C.
    Yildirim, E.
    Zinman, B.
    [J]. DIABETOLOGIA, 2019, 62 : S375 - S375
  • [45] The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
    Leiter, Lawrence A.
    Bain, Stephen C.
    Bhatt, Deepak L.
    Buse, John B.
    Mazer, C. David
    Pratley, Richard E.
    Rasmussen, Soren
    Ripa, Maria Sejersten
    Vrazic, Hrvoje
    Verma, Subodh
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (09): : 1690 - 1695
  • [46] Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials
    Verma, Subodh
    David, Jens-Peter
    Leiter, Lawrence A.
    Michelsen, Marie Mide
    Rasmussen, Soren
    Bhatt, Deepak L.
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2388 - 2392
  • [47] Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials
    Rubino, Domenica
    Angelene, Hanna
    Fabricatore, Anthony
    Ard, Jamy
    [J]. OBESITY, 2024, 32 (07) : 1268 - 1280
  • [48] Efficacy and safety of exenatide once weekly in patients with type 2 diabetes mellitus: a post hoc analysis of pooled data from the DURATION clinical trials
    Ruggles, J.
    Grimm, M.
    Han, J.
    Weaver, C.
    Griffin, P.
    Schulteis, C.
    Dong, H.
    Maggs, D.
    Malloy, J.
    [J]. DIABETOLOGIA, 2012, 55 : S329 - S329
  • [49] The effect of once-weekly semaglutide on MACE, blood pressure and lipids by race and ethnicity: a SUSTAIN 6 post hoc analysis
    Bain, S. C.
    Desouza, C. V.
    Gondolf, T.
    Hansen, T.
    Holst, I.
    Rea, R. R.
    Seufert, J.
    [J]. DIABETOLOGIA, 2019, 62 : S365 - S365
  • [50] KIDNEY DISEASE OUTCOMESWITH SEMAGLUTIDE VERSUS PLACEBO ACROSS BASELINE KDIGO RISK CATEGORIES: A POST HOC ANALYSIS OF SUSTAIN 6
    Tuttle, Katherine
    Bain, Stephen C.
    Bosch-Traberg, Heidrun
    Cherney, David
    Rasmussen, Soren
    Sokareva, Ekaterina
    Khunti, Kamlesh
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I145 - I146
12345